Atea Pharmaceuticals Q3 2024 GAAP EPS $(0.37) Beats $(0.49) Estimate
Benzinga Newsdesk 2 years ago
EarningsEarnings BeatsNews
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.49) by 24.49 percent. This is a 7.5 percent increase over losses of $(0.40) per share
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.49) by 24.49 percent. This is a 7.5 percent increase over losses of $(0.40) per share from the same period last year.